X
[{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm to Begin Clinical Trials Testing Avigan in COVID-19 Patients in Kuwait","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"U.S Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BARDA drafts Fujifilm Diosynth into its vaccine production effort, offering to also accelerate capacity expansion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm Diosynth Biotechnologies Expands Its Partnership with Novavax to Manufacture Covid-19 Vaccine Candidate at its Billingham Site","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr\u2019s Lead Therapeutic Candidate ATYR1923","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$100.0 million","newsHeadline":"Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amid Low Vaccine Demand, Novavax Pulls Out Of Fujifilm Manufacturing Deal And Inks $185M Settlement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FUJIFILM Diosynth Biotechnologies Enters into an Agreement with Argenx to Manufacture Efgartigimod, a Monoclonal Antibody (mAb) for the Treatment of Severe Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Fujifilm Diosynth Biotechnologies
Filters
Companies By Therapeutic Area
Details:
Under the agreement, FUJIFILM Diosynth Biotechnologies will provide drug substance manufacturing of efgartigimod (Vyvgart) at its large-scale biomanufacturing facility in Hillerod, Denmark.
Lead Product(s):
Efgartigimod
Therapeutic Area: Immunology Product Name: Vyvgart
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator:
Argenx
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: AgreementOctober 27, 2022
Details:
Novavax has been suffering from lower-than-expected demand for its COVID-19 vaccine (Nuvaxovid). Because of which Novavax will pay Fujifilm Diosynth Biotechnologies in a settlement tied to the "termination of manufacturing activity" at its CDMO partner.
Lead Product(s):
NVX-CoV2373,Matrix-M1
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator:
Novavax
Deal Size: $185.0 millionUpfront Cash: Undisclosed
Deal Type: TerminationSeptember 30, 2022
Details:
FUJIFILM will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its promising pipeline, including tabelecleucel (tab-cel®), ATA188, and allogeneic CAR T therapies.
Lead Product(s):
Tabelecleucel
Therapeutic Area: Immunology Product Name: Tab-cel
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Atara Biotherapeutics
Deal Size: UndisclosedUpfront Cash: $100.0 million
Deal Type: PartnershipApril 04, 2022
Details:
Under the agreement with FUJIFILM, will acquire Atara’s T-Cell Operations and Manufacturing facility. Atara with access to the flexible capacity needed to manufacture clinical and commercial stage allogeneic cell therapies for its pipeline, including tabelecleucel (tab-cel®).
Lead Product(s):
Tabelecleucel
Therapeutic Area: Immunology Product Name: Tab-cel
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Recipient:
Atara Biotherapeutics
Deal Size: $100.0 millionUpfront Cash: $100.0 million
Deal Type: PartnershipJanuary 26, 2022
Details:
Under the terms of the agreement, FUJIFILM Diosynth Biotechnologies will support process development and scale up of ATYR1923, including the manufacture of bulk drug substance for additional clinical trials in ILD.
Lead Product(s):
ATYR1923
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
aTyr Pharma
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: AgreementNovember 30, 2021
Details:
FUJIFILM's site in Billingham, UK will manufacture antigen component of NVX-CoV2373, Novavax' COVID-19 vaccine candidate. Billingham plans to begin production of the first batch at beginning of Q1, 2021.
Lead Product(s):
NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator:
Novavax
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: Expanded PartnershipAugust 17, 2020
Details:
FUJIFILM Diosynth Biotechnologies' College Station, Texas, site will support COVID-19 vaccine manufacturing, and Speed up U.S. government program to begin delivering millions of doses of COVID-19 vaccine to U.S. population.
Lead Product(s):
NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator:
BARDA
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: CollaborationAugust 03, 2020
Details:
FUJIFILM Diosynth will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.
Lead Product(s):
NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator:
U.S Government
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: CollaborationJuly 27, 2020
Details:
The Agreement aims to manufacture bulk drug substance for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. FDB’s site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373.
Lead Product(s):
NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I Product Type: Vaccine
Recipient:
Novavax
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: AgreementJuly 23, 2020
Details:
Avigan (favipiravir) is an antiviral medication largely used to treat influenza in Japan. It was approved in the country in 2014 and became a generic drug in 2019.
Lead Product(s):
Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator:
Dr. Reddy\'s Laboratories
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableJuly 21, 2020
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
